Drug Database
FI

filgrastim

✓ Approved

Laboratorio Elea · CSF3R · Recombinant Proteins

What is filgrastim?

filgrastim is a recombinant proteins developed by Laboratorio Elea. It is approved for therapeutic indications via injectable (others).

Drug Profile

CompanyLaboratorio Elea
Drug ClassRecombinant Proteins
Molecular TargetCSF3R
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Laboratorio Elea

Mechanism of Action

Molecular Targets

filgrastim acts on 1 molecular target:

CSF3Rcolony stimulating factor 3 receptor (CD114, GCSFR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

filgrastim is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Blood and lymphatic system disordersNeutropenia✓ Approved
Surgical and medical proceduresHaematopoietic stem cell mobilisation✓ Approved
Blood and lymphatic system disordersBone marrow disorder✓ Approved

Related Research Articles

PubMedJCO global oncology2026-08-20

Clinical Implications and Prevalence of Duffy-Null Associated Neutrophil Count in Patients With Breast Cancer of Middle Eastern Ethnicity.

Prem Sudha Shruti S, Abdelfattah Nabil M NM, Yetisyigit Tarkan T, Najeebi Taif T et al.

Duffy-null associated neutrophil count (DANC), formerly known as benign ethnic neutropenia, is seen in people of African and Middle Eastern descent and does not represent a true neutropenic state. Individuals with DANC can be identified by the Duffy-null phenotype on red cells. There is evidence that cancer patients with DANC are not at an increased risk of infection with chemotherapy. The aims of this study were to assess the prevalence of DANC among patients with breast cancer of Middle Eastern ethnicity and to study treatment delays, infectious complications, and survival in these patients. We retrospectively reviewed 493 patients with breast cancer treated in a referral oncology center in Bahrain. Patients with neutropenia or leukopenia at presentation with Duffy-null phenotype and no identifiable secondary causes of neutropenia were presumed to have DANC. Clinical details studied included treatment delays, filgrastim responsiveness, and episodes of febrile neutropenia. A contemporaneous group of patients with breast cancer without DANC were used for comparison. Seventy-two patients (14.6%) had a presumed diagnosis of DANC, and the median neutrophil count at presentation was 1.2 × 103/µL (range, 0.4-2.1 × 103/µL). Treatment delays and discontinuations were significantly more common in patients with DANC (P < .001) and were not decreased by prophylactic filgrastim use. Patients with DANC were uniformly filgrastim responsive, and only one patient had neutropenic fever. There was no effect of treatment delay or DANC on OS or PFS. DANC is prevalent among patients with breast cancer in Bahrain, and Duffy phenotyping on red cells can be a surrogate marker for diagnosis. Treatment delays because of the apparent neutropenia are common in DANC; however, febrile neutropenia is uncommon. This study is of particular relevance in populations with a high prevalence of DANC.

PMID 42623593
Read full article →
PubMedCureus2026-08-20

Cryptococcal Meningitis Revealing Late-Onset Combined Immunodeficiency After Two Decades of Recurrent Infections: A Case Report.

Martínez Evangelista Valeria J VJ, Munoz Plascencia Sandra S, Cárdenas-Favela Juan C JC, Correa Serrano Carlos A CA

Adult-onset inborn errors of immunity pose a significant diagnostic challenge because of their non-specific clinical presentation and frequent delay in diagnosis. We report a case of a 53-year-old woman with a nearly two-decade history of recurrent infections whose clinical course culminated in cryptococcal meningitis, prompting a comprehensive immunologic evaluation. Following the systematic exclusion of secondary causes of immunodeficiency, immunologic testing revealed hypogammaglobulinemia and profound CD4+ T-cell lymphopenia (188 cells/µL), consistent with combined humoral and cellular immune dysfunction and supporting classification within the late-onset combined immunodeficiency (LOCID) phenotype. Following appropriate antifungal therapy, subsequent immunoglobulin replacement therapy and filgrastim were associated with sustained clinical improvement. This case highlights that cryptococcal meningitis in HIV-negative patients should prompt a systematic evaluation for an underlying primary immunodeficiency and underscores the importance of recognizing the LOCID phenotype as an uncommon but potentially treatable cause of opportunistic infections in adults.

PMID 42621176
Read full article →
PubMedHematology, transfusion and cell therapy2026-07-31

Improving engraftment in autologous hematopoietic stem cell transplantation: comparing pegfilgrastim with filgrastim in an outpatient setting.

Gutierrez-Aguirre Cesar Homero CH, la Garza-Salazar Fernando De F, Gómez-Almaguer David D, Jaime-Pérez José Carlos JC et al.

Febrile neutropenia, a frequent complication in patients undergoing autologous stem cell transplantation, increases morbidity and hospitalization costs. The aim of this study was to compare the efficacy of two formulations of pegylated filgrastim with filgrastim in patients who received autologous stem cell transplantation as outpatients for lymphoma or myeloma. Thirty patients were randomized to receive a single 6 mg dose of either reference or biosimilar pegfilgrastim on Day +1. A retrospective Control Group of fifty-three patients who received filgrastim was included. The median times to neutrophil engraftment were 10, 9 and 11 days for the innovator pegfilgrastim, biosimilar pegfilgrastim (p-value = 0.14), and filgrastim (p-value = 0.0001), respectively. The median times to platelet engraftment were 10 days for both of the pegfilgrastim groups and 12 days for the filgrastim group (p-value = 0.0001). Febrile neutropenia incidence was lower in the pegfilgrastim group (6.7%) than in the filgrastim group (24.5%; p-value = 0.04). Cost analysis showed higher costs for the innovator pegfilgrastim, with filgrastim having the lowest cost of the three formulations. The innovator and the biosimilar pegfilgrastim demonstrated similar efficacy in engraftment speed and febrile neutropenia incidence. Pegfilgrastim was associated with faster engraftment, a lower incidence of platelet transfusion, and a lower incidence of febrile neutropenia.

PMID 42531780
Read full article →
PubMedImmunotherapy advances2026-07-25

Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer.

Parent Brendan D BD, Kelly Anthony E AE, Hoffman Megan T MT, Dougan Michael M et al.

Growth factors, including granulocyte colony-stimulating factor (G-CSF; pegfilgrastim, filgrastim), are used for prophylaxis or treatment of chemotherapy-induced neutropenia, yet their effects on antitumour immunity remain incompletely understood. We previously found that serum from patients with pancreatic ductal adenocarcinoma (PDAC) treated with multiagent chemotherapy plus G-CSF drove differentiation of T cell-suppressive monocytes in vitro, suggesting that supportive care interventions may shape immune responses in this disease. We evaluated the immunologic and therapeutic impact of G-CSF in two murine PDAC models that differ in their baseline frequencies of infiltrating T cells and in their responsiveness to checkpoint blockade immunotherapy. In poorly immunogenic, T-cell-low tumours, use of G-CSF did not affect tumour growth or response to chemo- or immunotherapy, although neutrophil recovery was improved in mice receiving FOLFIRINOX and G-CSF compared to chemotherapy alone. In immunogenic tumours with a robust endogenous T-cell response, combination anti-PD1 and anti-CTLA-4 therapy resulted in durable tumour clearance. Combination with G-CSF diminished the effectiveness of checkpoint blockade and resulted in significantly fewer cured mice. G-CSF, commonly used for supportive care with FOLFIRINOX and other chemotherapy regimens, induces systemic immune suppression that can reduce the efficacy of T-cell-targeting immunotherapies.

PMID 42500327
Read full article →
PubMedLa Revue de medecine interne2026-07-23

[Sustained complete remission achieved with tofacitinib in a refractory T-cell large granular lymphocytic leukemia].

Carré Adèle A, Deshayes Samuel S, Martin-Silva Nicolas N, Comoz François F et al.

Treatment of large granular lymphocytic leukemia, particularly T-cell leukemia (LGL-T), remains challenging. JAK inhibitors, although still scarcely evaluated, appear promising. An 85-year-old woman was treated for a refractory LGL-T associated with neutropenia, unclassified polyarthritis and vitiligo. During the 7-year course of the disease, she received alternatively cyclosporine, cyclophosphamide and methotrexate, associated with prednisone and/or filgrastim. During a severe relapse with agranulocytosis complicated by infectious pneumonia, no response was observed after 14 days of filgrastim. Ten days after initiation of tofacitinib, a marked increase of the neutrophil count (98G/L) occurred, associated with Sweet syndrome. Both resolved rapidly with filgrastim discontinuation. Tofacitinib allowed a rapid and complete remission of both hematological and clinical manifestations, which was maintained throughout 37 months of follow-up. This report adds to the limited evidence supporting tofacitinib in LGL-T and further highlights the potential of JAK-inhibition, particularly in refractory and systemic forms.

PMID 42486736
Read full article →
PubMedInternational journal of clinical oncology2026-07-23

Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.

Nitani Chika C, Hara Junichi J, Kawamoto Hiroshi H, Taguchi Tomoaki T et al.

Granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin and isotretinoin are unavailable in Japan, necessitating alternative cytokines for dinutuximab immunotherapy. We compared the efficacy of a regimen containing granulocyte colony-stimulating factor (G-CSF)/teceleukin (regimen A) to that with GM-CSF/aldesleukin/isotretinoin (regimen B) in children with newly diagnosed high-risk neuroblastoma. After completing initial therapy including high-dose chemotherapy followed by autologous stem cell transplantation and radiotherapy, children with non-progressive disease were randomized to regimen A or B. Regimen B was identical to the immunotherapy regimen tested in ANBL0032 (six cycles of isotretinoin and five concomitant cycles of dinutuximab alternating with GM-CSF and aldesleukin). Regimen A consisted of six cycles of dinutuximab alternating with G-CSF and teceleukin. Event-free survival (EFS) and overall survival (OS) were compared between two regimens. In total, 35 patients (16 receiving regimen A and 19 receiving regimen B) were enrolled. The 2-year EFS was 80.8% for patients receiving regimen A and 62.3% for those receiving regimen B, and their OS rates were 93.8% and 100.0%, respectively. The hazard ratio of regimen A compared to regimen B for EFS was 0.494 (upper limit of one-sided 70% confidence interval: 0.710), suggesting comparable efficacy of the two regimens. Frequently recorded grade 3/4 adverse events were fever, infection, and hematologic toxicity with no obvious difference in incidence between the regimens. Our results suggest that the efficacy of the alternative regimen containing G-CSF is comparable to that of the ANBL0032 regimen, providing a rationale for further evaluation in a phase III trial.

PMID 42490004
Read full article →

+2282 more articles available with a free account

Sign up free to view all articles →

Ask about filgrastim